OR Oncology Reports 1021-335X 1791-2431 D.A. Spandidos 10.3892/or.2017.5378 or-37-03-1521 Articles Cripto-1 promotes epithelial-mesenchymal transition in prostate cancer via Wnt/β-catenin signaling LiuYan 1 QinZhenbang 1 YangKuo 1 LiuRanlu 1 2 XuYong 1 2 Prostate Disease Laboratory, Tianjin Institute of Urology, Tianjin 300211, P.R. China Department of Urology, The Second Hospital of Tianjin Medical University, Tianjin 300211, P.R. China Correspondence to: Professor Yong Xu, Department of Urology, The Second Hospital of Tianjin Medical University, 23 Pingjiang Road, Hexi, Tianjin 300211, P.R. China, E-mail: xuyong8816@sina.com 032017 17012017 37 3 1521 1528 01082016 21122016 Copyright © 2017, Spandidos Publications 2017

The Cripto-1 (CR-1) derived EGF-CFC family was overexpressed in tumor development enhancing proliferation, epithelial-mesenchymal transition (EMT) and migration of tumor cells. However, correlation between CR-1 and prostate cancer (PCa) remains still unclear. In the present study, we proved that CR-1 was expressed in PCa and its function was in the progression of PCa. Compared with benign prostatic hyperplasia (BPH) tissues, we confirmed that PCa tissues had high expression of CR-1 by immunohistochemistry and statistical data showed that CR-1 promoted properties of EMT in PCa tissues, including the downregulation of the cell adhesion molecules β-catenin (membrane) and E-cadherin while upregulating transcription factors β-catenin. Overexpression of CR-1 had close relationship with PSA, Gleason, clinical staging and lymph node metastasis in PCa patients. Then, we found that PC-3 cells transfected with CR-1-shRNA inhibited EMT using RT-PCR, RT-qPCR, western blotting and immunofluorescence. Also, we evaluated cell invasive ability in vitro by Transwell and wound-healing assay. Our data showed that transfected CR-1-shRNA altered EMT including β-catenin, E-cadherin, c-myc, GSK-3, p-GSK and Wnt/β-catenin pathway in PC-3. It also suppressed PC-3 cell migration. Additionally, our results displayed that Licl had antitumor activity against PC-3 through the inhibition of Wnt/β-catenin pathway. Inhibition of cell viability was dose-time dependent. The present study proved that CR-1 regulates EMT of PCa by Wnt/β-catenin pathway. Hence, CR-1 may provide a new biological marker, and possibly contributes to clinical treatment against PCa.

 cripto-1 epithelial-mesenchymal transition prostate cancer Wnt/β-catenin signaling pathway Introduction

Prostate cancer (PCa) is generally diagnosed with malignant tumor and this is important in terms of mortality. Approxiamtely 180,890 new cases are estimated for 2016 and more than 26,120 PCa deaths will occur in the USA. PCa has exceeded lung cancer in men accounting for 21% of all male malignancies. PCa is also the second cause of death in men (1). Its incidence rates vary between countries. Incidence rate of PCa in Asia is widely accepted to be the lowest all over the world. However, it has gradually increased recently (2). Aside from age and race, the risk factor for PCa is a family history of the disease. In addition, its greater prevalence in the west implicates lifestyle and environmental risk factors (3). Currently, there is no reliable prediction methods and effective clinical therapies for PCa. However, similar to other human malignancies, clinical relevance of genetics and molecular mechanism supporting PCa development and progression remain poorly understood.

CR-1 is an EGF-CFC family member gene (4). CR-1 was primitively found from NTERA2 (5). The anchor protein CR-1 contains extracellular signal sequence, EGF-like domain and CFC-motif, GPI attachment. CR-1 takes actively part in the mediation of the embryonic development and malignant tumor occurrence (6). CR-1 is an obligatory co-receptor during embryogenesis (7). CR-1 is expressed at low level in adults. In contrast, high levels of CR-1 are detected in many cancer patients (8). CR-1 plays important roles in promoting tumor cell progression, stimulating cell proliferation and invasion between epithelial-mesenchymal transition (EMT) (9,10).

Previous research has reported that different kinds of cells in the embryonic development and progression of malignant tumor share common signaling pathways. The study of Wechselberger et al (11) revealed that CR-1 might be a mediator of the effects of activated Wnt/β-catenin pathway in hyperplasia and adenocarcinoma of mouse mammary gland (12,13). Epithelial-mesenchymal transition (EMT) can promote attached epithelial cells into individual migration into the extracellular matrix (14). Prasad et al (15) reported that Wnt/β-catenin signaling upregulated invasion of breast cancer cells. It contained E-cadherin and GSK3β in implementing EMT. Wnt/β-catenin pathway contributed to epithelial tissue inducing EMT to produce signal transduction pathways. Thus, we hypothesized that CR-1 would promote PCa occurrence by the Wnt/β-catenin pathway.

Now, we describe connection of CR-1 and EMT with PCa tissues. We found an important role of CR-1 in PCa cells by the Wnt/β-catenin pathway. Furthermore, CR-1 positively regulated invasion, migration and EMT. These results shed light on the mechanisms by which PCa occurs, develops and provides evidence for CR-1 as a new biological marker contributing to clinical treatment against PCa.

 Materials and methods <sec> <title>Human prostate specimens

The present study on human prostate specimens was approved by the Ethics Committee of the Second Hospital of Tianjin Medical University. Specimens were obtained from patients with signed informed consent for use in research. Patient tissues were collected immediately and then were quickly frozen with liquid nitrogen. Patients did not receive therapy before surgery. Prostate cancer tissues were collected after radical prostatectomy at the Department of Urology of the hospital. Adjacent normal tissues were gained from the same patients. Hematoxylin and eosin (H&E) staining sections were used to identify the tissues by pathologists.

 Cell culture

LNCap, PC-3 and RWPE-1 were maintained in our laboratory. LNCap and PC-3 were cultivated in RPMI-1640 medium (Gibco, Shanghai, China) with 10% fetal bovine serum (FBS). RWPE-1 was incubated in keratinocyte serum-free medium (K-SFM; Gibco). All the cells were incubated at 37°C and 5% CO2.

 Plasmid construction and cell transfection

According to the shRNA design principle, four suitable shRNA target sequences (sh1-4), from human CR-1 gene GenBank accession no. NM_001174136.1, were synthesized, respectively: sh-1, CCA TCAGGAATTTGCTCGTCC; sh-2, GCAAATTTCATGAC CAGTAAA; sh-3, CCTAACTGAAAGATGATCATT; and sh-4 CCAAGGTCTTCTTAATATGTT. A small hairpin RNA (shRNA) of CR-1 exists in psi-U6.1 vector. GeneCopoeia constructed plasmids with enhanced green fluorescent protein (EGFP) and puromycin resistance (cat. no. HSH060851-CU6; GeneCopoeia, Guangzhou, China). We transfected the plasmid when PC-3 cells were 90% confluent. Lipofectamine 2000 (Invitrogen) was in strict accordance with the instructions of the manufacturer. Fluorescence microscopy was used to observe the transfection efficiency.

 Immunohistochemical (IHC) staining. Sixty PCa and 60 BPH tissues were collected from the Urology Department

Xylene was used to deparaffinize and hydrate paraffin-embedded sections (4 µm) followed by graded alcohols to water; 0.01 M citrate for 10 min was used for antigen retrieval. Then slowly cooled down. Primary antibodies, horseradish peroxidase and DAB were then used, respectively (Beijing Zhongshan Golden Bridge, Beijing, China). Finally, sections were counterstained and dehydrated. Antibodies were as follows: anti-CR-1 (Sigma-Aldrich) anti-β-catenin and anti-E-cadherin (Beijing Zhongshan Golden Bridge).

 Immunofluorescence (IF)

For detection of CR-1, E-cadherin and β-catenin cells were put on the coverslips. Paraformaldehyde (4%), 0.1% Triton X-100, primary antibodies and secondary antibodies were then used. The secondary antibodies were labeled by conjugation for 90 min at RT in the dark. After washing, DAPI stained cells for 5 min. After extensive washing, cells were mounted on glass slides with antifade solution and the fluorescence was visualized by laser scanning confocal microscopy using a 200x lens (FV1000; Olympus Optical, Co., Ltd., Tokyo, Japan).

 MTT assay (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide)

PC-3 was placed with 1×104 cells/well. Lithium chlorides (Licl) have different concentrations at various time intervals (12, 24 and 48 h). Next, each well was added with MTT solution. Then, each well was put into dimethyl sulfoxide (DMSO) and rotated at room temperature (RT). The absorbance value was measured with microplate reader at 570 nm (BioTek Instruments, Inc., Winooski, VT, USA).

 RT-qPCR and RT-PCR assay

EasyPure® kit (TransGen Biotech, Inc., Beijing, China) was applied to extract total RNA. We applied TransScript® SuperMix (TransGen Biotech) to synthesis of cDNA. RT-qPCR was used with SYBR-Green Master Mix kit (Roche, Basel, Switzerland) and GADPH was used as the internal reference. Samples were denaturized at 95°C for 10 min, followed by 45 cycles at 95°C for 15 sec, 60°C for 30 sec and 72°C for 15 sec. cDNA template was amplified with 2X EasyTaq® PCR Mix (TransGen Biotech) for RT-PCR. Reaction conditions were 94°C for 5 min, 35 cycles of: 94°C for 30 sec, 60°C for 30 sec and 72°C for 60 sec and 72°C for 10 min. Then, samples were electrophoresed with 2.5% agarose gel. The primers (Sangon Biotech Co., Ltd., Shanghai, China) were designed as showen in Table I. Each sample was run in triplicate.

 Western blotting

For analyzing the expression of related proteins, standard methods were performed as previously described (16). β-catenin, E-cadherin, c-myc, GSK-3β and p-GSK-3β (1:500; Bioworld Technology, Inc., St. Louis Park, MN, USA) were used for the primary antibody; GADPH was used as loading control (1:1,000; Bioworld Technology).

 Wound healing test

PC-3 was incubated up to 90% confluence and transfected in 6-well plates. After 48 h, cells were scraped with a pipette tip. Then, the cells were further incubated for 12 and 24 h. Wounded regions were photographed at ×40 amplification using computer-aided microscopy (Nikon Eclipse Ti-U; Nikon, Tokyo, Japan). Captured image were obtained 0, 12 and 24 h after the wounding. The distance the cells migrated was measured and analyzed using FV10-ASW 4.0 Viewer cell image analysis software (Olympus).

 Transwell invasion assay

Assay was implemented using Transwell inserts (Corning, Inc., Corning, NY, USA) with Matrigel matrixes (BD Biosciences, San Jose, CA, USA) in 24-well plates. A total of 1×105/ml transfected PC-3 cells were added into the apical chamber and RPMI-1640 was added into basolateral chamber. Cells were then cultured for 24 h. Inserts were scraped with cotton swabs and fixed in paraformaldehyde. In addition, then they were added with crystal violet. The PC-3 cells on permeable membrane were distinguished using microscope with a camera.

 Statistical analysis

We used the GraphPad Prism 5.0 and the SPSS 16.0. We established the statistically significant difference making use of two-tailed Student's t-test, Chi-square test and McNemar's statistical test. P<0.05 and P<0.01 were deemed statistically significant.

 Results <sec> <title>CR-1 is highly expressed and correlated with EMT in PCa tissues

We elected 60 PCa and 60 BPH patient tissues for immunohistochemistry. In BPH tissues, CR-1 expression was low at levels; however, CR-1 expression was high in PCa tissues. Thus, CR-1 was overexpressed in PCa tissues (Fig. 1A). CR-1 expression in PC-3 cells was the highest of all the cells (Fig. 1B). In our studies, immunohistochemistry staining showed that CR-1 was predominantly localized to the cytoplasm of PCa cells. Immunofluorescence (IF) showed that CR-1 protein was expressed both in the nucleus and cytoplasm, but mainly in the cytoplasm (Fig. 1C). CR-1 levels positively correlated with β-catenin in the cytoplasm (P<0.05). CR-1 levels were contrary to the E-CD levels (P<0.05) (Table II). Table III shows the relationship between the CR-1 expression and the clinicopathological parameters. Expression of CR-1 has no correlation with age; however, overexpression of CR-1 and PSA (<4 vs. 4–10 vs. >10 ng/ml; P<0.01), Gleason (≤7 vs. >7; P<0.05), clinical staging (I–II vs. III–IV; P<0.05) and lymph node metastasis (no vs. positive; P<0.05) had close relationships. We suggest that CR-1 was closely linked with PCa progression and relative EMT marker protein.

 Expression of mRNA and protein in prostate cells and tissues

We used RT-PCR, RT-qPCR and western blot technology to detect CR-1 in prostate cells and tissues. CR-1 level was shown in the prostate specimens (PCa tissues, n=10; near tumor tissues, n=10) using RT-PCR and RT-qPCR (Fig. 2A and C). In comparison with the near tumor tissues, upregulated CR-1 (P=0.0187) was displayed in PCa tissues (Fig. 2A, C and D). Expression of CR-1 was higher in PC-3 cells (Fig. 2B). Thus, we used the PC-3 cell line for the next experiment in PCa.

 Expression of EMT relative protein after CR-1 shRNA transfection in PC-3

After PC-3 cell transfection with shRNA, CR-1 expression was downregulated. Expression of the CR-1-shRNA plasmid vector (NC/CR-1-shRNA1-4) decreased red fluorescent protein (RFP) was evaluated using scanning confocal microscopy in PC-3. We counted transfection efficiency under a fluorescent microscope for 48 h after transfection. CR-1-shRNA-3 had the most preferable interference effect (Fig. 4A). CR-1-shRNA-3 was selected for the next experiments. β-catenin (a Wnt signaling pathways marker) and E-cadherin (an epithelial marker) was examined in cytoplasm by scanning confocal microscopy (Fig. 4B). β-catenin was prominently expressed at low level throughout the cytoplasm of PC-3 cells; whereas, a significantly enhanced E-CD was detected. Expression of CR-1 and EMT markers in PC-3 prompted us to examine whether CR-1 silencing could be in lost in mesenchymal and gained in epithelial markers. To further determine if this transformation represented an EMT, RT-PCR and western blotting were used to show the relationship between CR-1 and EMT. We found that c-myc was markedly decreased by stable transfection with CR-1-shRNA-3. In addition, β-catenin levels were increased in the membrane, while E-cadherin expression levels were also higher in PC-3 CR-1-shRNA-3 cells (Fig. 5). Thus, our data demonstrated that CR-1 likely plays a crucial part in mediating the EMT in PC-3 cells.

 Identification of the characteristic protein and signal pathways associated with EMT in CR-1 silencing PC-3 cells after adding Licl

MTT assay demonstrated that after the treatment with different concentrations of Licl, proliferation of PC-3 cell was significantly decreased and cells appeared shrunken and non-viable. Inhibiting effect of Licl was dose-dependent (Fig. 3). We adopted 40 mmol/l of Licl for 48 h to inhibit the tumor growth of PC-3 by Wnt/β-catenin pathway. To explore which pathways were activated during EMT mediated by CR-1, we adopted 5 differentially expressed genes regulated by CR-1 silencing in PC-3 cells after adding Licl. As shown in Fig. 6 we also especially focused on the relationship between CR-1 and Wnt/β-catenin pathway. Licl (Wnt/β-catenin pathway inhibitors) was pretreated in CR-1 silenced PC-3. Licl upregulated E-cadherin, β-catenin and p-GSK-3β in CR-1 silenced PC-3 cell lines. In accordance with mRNA, western blotting revealed that the effects of CR-1 on enhancing EMT phenotype were eliminated in Licl pretreated groups. GSK-3β and c-myc were downregulated (Fig. 6). We demonstrated that CR-1 acted by Wnt/β-catenin pathway inducing EMT.

 To investigate the invasion effects of silencing CR-1 in PC-3

CR-1 silencing (CR-1-shRNA-3) and vector control (VC) cells from PC-3 were established. Transwell assay revealed that silencing CR-1 strongly suppressed the invasive ability in PC-3 compared to non-transfected PC-3 or CR-1-VC-shRNA-3 cells (both P<0.05) (Fig. 7A). High expression of CR-1 was proved to strengthen invasiveness in PC-3 cells. In addition, wound healing assay showed that silencing CR-1 decreased healing speed of the scratch in transfected cells. Wound closure rate of CR-1-shRNA-3-PC3 cells was significantly less than that of non-transfected PC-3 cells and CR-1-VC-shRNA-3-PC3 cells (both P<0.05). No obvious differences in the wound closure rates between CR-1-VC-shRNA-3-PC3 cells and non-transfected PC-3 cells were detected (Fig. 7B). Collectively, these data indicated that CR-1 stimulated PCa cell invasiveness.

 Discussion

In the present study, high expression levels of CR-1 were observed in PCa which is consistent with previous studies. Reports illustrated that CR-1 upregulated due to the EGF-CFC family members (4,17). Gene expressions have shown an important role of CR-1 by Wnt/β-catenin pathway in PCa cells. CR-1 positively regulated proliferation, invasion and migration leading to EMT. These findings provided strong evidence that elevated CR-1 promotes metastatic ability, EMT and stages of tumor progression via Wnt/β-catenin pathway in PC-3, which further supported that CR-1 could be a therapeutic target in PCa.

Since the role of CR-1 promotes tumor progression via signaling pathway in tumor cells, some studies have focused on CR-1 in colon, breast, gastric cancer, hepatocellular carcinoma, pancreatic and bladder cancer (12,18–20). It was found that CR-1 stimulated cell proliferation and EMT (21). Bianco et al (22) showed that CR-1 activated the ras/raf/MAPK pathway and suppressed epithelial cells. Shukla et al (23) reported that CR-1 was overexpressed in mouse skin carcinogenesis. Xu et al (24) found that the serum CR-1 levels were extremely high in lung cancer patients. Another study also found the same conclusion (11). Here, IHC showed that CR-1 expressed mainly in PCa cytoplasm, which was in accordance with the report of Gong et al in breast cancer (25). Furthermore, CR-1 had a positive correlation with the patient PSA level, Gleason, clinical stage and lymph node metastasis.

A correlation between CR-1 and EMT marker was also found in PCa. In the EMT process, downregulation of E-cadherin can cause cellular changes in different aspects (26,27). Our present findings indicated that CR-1 silencing resulted in marked changes in the reduction of mesenchymal proteins and the appearance of epithelial proteins. E-cadherin levels increased in CR-1 silenced PC-3 cells with a concomitant increase in β-catenin expression in membranes. In part, CR-1 could regulate EMT by activating Wnt/β-catenin pathway in PC-3 cells. We found that silencing of CR-1 led to β-catenin c-myc and GSK-3β downregulation. Zhong et al (28) indicated that overexpressed CR-1 led to lower expression of E-CD in gastric cancer patients. CR-1 and E-cadherin show potential to become valuable markers for diagnosing and monitoring of gastric cancer. Similarly, activated CR-1 induced EMT in HC-11 and Eph4 cells, in which E-cadherin was downregulated (29). The accumulated data strongly suggested that silencing of CR-1 might regulate the process of EMT through downregulation of GSK-3β to activation of E-cadherin. This agrees with Strizzi et al (9) who demonstrated that CR-1 was well correlated with EMT marker proteins.

In the present study, we found that after adding Licl, proliferation of PC-3 cells was decreased. Cell inhibition rates were time- and concentration-dependent. Hou et al (30) also reported that Licl disrupted DNA replication and suppressed PCa cell growth, which was in accordance with our research. Furthermore, some other evidence reported that Licl was a direct inhibitor of GSK-3β which induced GSK-3β N-terminal phosphorylation (31). Licl was used to pretreat CR-1 silencing PC-3 cells. Our results found that the levels of GSK-3β and c-myc were substantially inhibited by CR-1 silencing after adding Licl, whereas, it increased the levels of β-catenin, p-GSK-3β and E-CD by means of Wnt/β-catenin pathway, compared with the IF control groups. Our data suggested that CR-1 activated by Wnt/β-catenin induced EMT in PC-3.

In addition, we applied the Transwell assay to observe cell invasiveness after CR-1 silencing. Silencing CR-1 by shRNA interference attenuates the CR-1-stimulation-induced migration and invasion. Results from cells in vitro invasion indicated that the number of cells that penetrated the basal membrane from silenced CR-1 group was significantly less than vector control group. Loss of CR-1 suppressed invasion of PCa cells. After downregulation of CR-1 expression, the cell invasive ability and proliferation rate in PC-3 cells was significantly decreased. Similarly, Huang and colleagues (32) reported that CR-1 interference significantly reduced the migratory activity of cells, suggesting that CR-1 enhanced cell invasiveness in esophageal squamous cell carcinoma. Wu et al (33) also reported the same conclusion in nasopharyngeal carcinoma. In brief, CR-1 stimulated PCa cell invasiveness via the activation of Wnt/β-catenin pathway.

Our key finding is that activated CR-1 can increase the proliferation and invasion of PCa cells. Levels of EMT relative proteins were changed in CR-1 silenced PC-3 when Wnt/β-catenin signaling pathway was activated. This result indicated that CR-1 activated Wnt/β-catenin signaling pathway and promoted the occurrence of EMT in PCa. CR-1 may serve as a new biological marker for clinical treatment against PCa.

 Acknowledgements

The present study was supported by grants (81472416) from the National Natural Science Foundation of China and grants (20140122) from the Tianjin Municipal Education Commission.

 References SiegelRLMillerKDJemalACancer statistics, 2016CA Cancer J Clin66730201610.3322/caac.2133226742998 CenterMMJemalALortet-TieulentJWardEFerlayJBrawleyOBrayFInternational variation in prostate cancer incidence and mortality ratesEur Urol6110791092201210.1016/j.eururo.2012.02.05422424666 AttardGParkerCEelesRASchröderFTomlinsSATannockIDrakeCGde BonoJSProstate cancerLancet3877082201610.1016/S0140-6736(14)61947-426074382 SalomanDSBiancoCEbertADKhanNIDe SantisMNormannoNWechselbergerCSenoMWilliamsKSanicolaMThe EGF-CFC family: Novel epidermal growth factor-related proteins in development and cancerEndocr Relat Cancer7199226200010.1677/erc.0.007019911174844 CiccodicolaADonoRObiciSSimeoneAZolloMPersicoMGMolecular characterization of a gene of the ‘EGF family’ expressed in undifferentiated human NTERA2 teratocarcinoma cellsEMBO J81987199119892792079401069 BiancoCRangelMCCastroNPNagaokaTRollmanKGonzalesMSalomonDSRole of Cripto-1 in stem cell maintenance and malignant progressionAm J Pathol177532540201010.2353/ajpath.2010.100102206163452913337 BiancoCStrizziLNormannoNKhanNSalomonDSCripto-1: An oncofetal gene with many facesCurr Top Dev Biol6785133200510.1016/S0070-2153(05)67003-215949532 De CastroNPRangelMCNagaokaTSalomonDSBiancoCCripto-1: An embryonic gene that promotes tumorigenesisFuture Oncol611271142201010.2217/fon.10.6820624125 StrizziLBiancoCNormannoNSenoMWechselbergerCWallace-JonesBKhanNIHirotaMSunYSanicolaMEpithelial mesenchymal transition is a characteristic of hyperplasias and tumors in mammary gland from MMTV-Cripto-1 transgenic miceJ Cell Physiol201266276200410.1002/jcp.2006215334661 WechselbergerCEbertADBiancoCKhanNISunYWallace-JonesBMontesanoRSalomonDSCripto-1 enhances migration and branching morphogenesis of mouse mammary epithelial cellsExp Cell Res26695105200110.1006/excr.2001.519511339828 WechselbergerCStrizziLKenneyNHirotaMSunYEbertAOrozcoOBiancoCKhanNIWallace-JonesBHuman Cripto-1 overexpression in the mouse mammary gland results in the development of hyperplasia and adenocarcinomaOncogene2440944105200510.1038/sj.onc.120841715897912 StrizziLBiancoCNormannoNSalomonDCripto-1: A multifunctional modulator during embryogenesis and oncogenesisOncogene2457315741200510.1038/sj.onc.120891816123806 RangelMCKarasawaHCastroNPNagaokaTSalomonDSBiancoCRole of Cripto-1 during epithelial-to-mesenchymal transition in development and cancerAm J Pathol18021882200201210.1016/j.ajpath.2012.02.031225424933378914 AcloqueHAdamsMSFishwickKBronner-FraserMNietoMAEpithelial-mesenchymal transitions: The importance of changing cell state in development and diseaseJ Clin Invest11914381449200910.1172/JCI38019194878202689100 PrasadCPRathGMathurSBhatnagarDParshadRRalhanRExpression analysis of E-cadherin, Slug and GSK3beta in invasive ductal carcinoma of breastBMC Cancer9325200910.1186/1471-2407-9-325197515082753637 LiYCheQBianYZhouQJiangFTongHKeJWangKWanXPAutocrine motility factor promotes epithelial-mesenchymal transition in endometrial cancer via MAPK signaling pathwayInt J Oncol4710171024201526201353 AdamsonEDMinchiottiGSalomonDSCripto: A tumor growth factor and moreJ Cell Physiol190267278200210.1002/jcp.1007211857442 BiancoCNormannoNDe LucaAMaielloMRWechselbergerCSunYKhanNAdkinsHSanicolaMVonderhaarBDetection and localization of Cripto-1 binding in mouse mammary epithelial cells and in the mouse mammary gland using an immunoglobulin-cripto-1 fusion proteinJ Cell Physiol1907482200210.1002/jcp.1003711807813 WeiBJinWRuanJXuZZhouYLiangJChengHJinKHuangXLuPCripto-1 expression and its prognostic value in human bladder cancer patientsTumour Biol3611051113201510.1007/s13277-014-2695-125326807 WangJHWeiWXuJGuoZXXiaoCZZhangYFJianPEWuXLShiMGuoRPElevated expression of Cripto-1 correlates with poor prognosis in hepatocellular carcinomaOncotarget635116351282015263756694741514 NagaokaTKarasawaHCastroNPRangelMCSalomonDSBiancoCAn evolving web of signaling networks regulated by Cripto-1Growth Factors301321201210.3109/08977194.2011.64196222149969 BiancoCCastroNPBaratyCRollmanKHeldNRangelMCKarasawaHGonzalesMStrizziLSalomonDSRegulation of human Cripto-1 expression by nuclear receptors and DNA promoter methylation in human embryonal and breast cancer cellsJ Cell Physiol22811741188201310.1002/jcp.24271231293423573215 ShuklaAHoYLiuXRyscavageAGlickABCripto-1 alters keratinocyte differentiation via blockade of transforming growth factor-beta1 signaling: Role in skin carcinogenesisMol Cancer Res6509516200810.1158/1541-7786.MCR-07-039618337457 XuCHWangYQianLHYuLKZhangXWWangQBSerum Cripto-1 is a novel biomarker for non-small cell lung cancer diagnosis and prognosisClin Respir JNov252015(Epub ahead of print) doi: 10.1111/crj.1241410.1111/crj.12414 GongYPYarrowPMCarmaltHLKwunSYKennedyCWLinBPXingPXGillettDJOverexpression of Cripto and its prognostic significance in breast cancer: A study with long-term survivalEur J Surg Oncol33438443200710.1016/j.ejso.2006.10.01417125961 YangJWeinbergRAEpithelial-mesenchymal transition: At the crossroads of development and tumor metastasisDev Cell14818829200810.1016/j.devcel.2008.05.00918539112 KlauzinskaMCastroNPRangelMCSpikeBTGrayPCBertoletteDCuttittaFSalomonDThe multifaceted role of the embryonic gene Cripto-1 in cancer, stem cells and epithelial-mesenchymal transitionSemin Cancer Biol295158201410.1016/j.semcancer.2014.08.00325153355 ZhongXYZhangLHJiaSQShiTNiuZJDuHZhangGGHuYLuAPLiJYPositive association of up-regulated Cripto-1 and down-regulated E-cadherin with tumour progression and poor prognosis in gastric cancerHistopathology52560568200810.1111/j.1365-2559.2008.02971.x18312357 StrizziLBiancoCRaafatAAbdallahWChangCRaafatDHirotaMHamadaSSunYNormannoNNetrin-1 regulates invasion and migration of mouse mammary epithelial cells overexpressing Cripto-1 in vitro and in vivoJ Cell Sci11846334643200510.1242/jcs.0257416176936 HouCLZhangZHHuangDLSunAJLiCl suppresses tumor growth and inhibits DNA replication in prostate cancerZhonghua Bing Li Xue Za Zhi414754782012(In Chinese)22932460 ZhangFPhielCJSpeceLGurvichNKleinPSInhibitory phosphorylation of glycogen synthase kinase-3 (GSK-3) in response to lithium. Evidence for autoregulation of GSK-3J Biol Chem2783306733077200310.1074/jbc.M21263520012796505 HuangCChenWWangXZhaoJLiQFuZCripto-1 promotes the epithelial-mesenchymal transition in esophageal squamous cell carcinoma cellsEvid Based Complement Alternat Med2015421285201510.1155/2015/421285264729844589627 WuZLiGWuLWengDLiXYaoKCripto-1 overexpression is involved in the tumorigenesis of nasopharyngeal carcinomaBMC Cancer9315200910.1186/1471-2407-9-315197324642751776

Correlation between CR-1 expression and EMT in PCa specimens. (A) Immunohistochemical CR-1, E-CD and β-catenin protein expression in BPH and PCa tissues (magnification, ×200). (B) Immunohistochemical CR-1 protein expression in PC-3 cells, LNCap cells and RWPE-1 cells (magnification, ×100). Brown granules in the cytoplasm are CR-1 protein. (C) No or weak expression of CR in RWPE-1, strong cytoplasm and cell nucleus expression of CR-1 in the majority of PC-3 (magnification, ×200).

CR-1 gene is expressed in prostate tissues and cells. (A) Expression of CR-1 in PCa tissues and near tumor tissues was assessed by RT-qPCR (P<0.05). (B) CR-1 in PCa cell lines were verified using RT-qPCR (P<0.05). Levels near tumor tissues and in RWPE-1 were regarded as 100% (A and B), and PCa tissues were compared with near tumor tissues, and RWPE-1 was compared with PC-3 and LNCap. (C) CR-1 in PCa and near tumor tissues was detected by RT-PCR. PCR results were analyzed. (D) CR-1 in PCa and near tumor tissues was verified using western blotting.

Impact of Licl consists in the cell viability of PC-3 cells. Cells (1×104 cells/well) were measured on 0, 12, 24 and 48 h after the mixture with different concentrations of Licl.

(A) CR-1 shRNA plasmid (CR-1-shRNA1-4) constuction and PC-3 cell transfection (magnification, ×200). (B) Wnt/β-catenin signaling pathway marker β-catenin (green) and epithelial marker E-cadherin (red) were visualized by immunofluorescence following staining for nucleus with DAPI (blue) in PC-3 cells transfected with PBS, vector control and CR-1-shRNA-3 (magnification, ×200).

Silencing of CR-1 reverses the EMT phenotype in PC-3 cells. (A) CR-1 silencing of PC-3 cells were EMT-relative at mRNA levels. (β-actin, internal reference). (B) CR-1 silencing PC-3 cells were EMT-relative proteins. (GAPDH, internal reference) (*P<0.01 and **P<0.05).

Impact of Licl on the cell EMT phenotype in CR-1 silencing PC-3 cells. (A) After adding Licl, gene expression of relative EMT in CR-1 silencing PC-3. (β-actin, internal reference). (B) After adding Licl, relative EMT proteins in CR-1 silencing PC-3. (GAPDH, internal reference) (*P<0.01; **P<0.05).

CR-1 actively regulating the invasiveness of PCa. (A) Transwell assay showing cell invasion in PC-3 cells (magnification, ×200). (B) Wound healing assay showing cell migration (magnification, ×40) (*P<0.05).

Primer for RT-PCR and RT-qPCR.

Gene Forward primer Reverse primer Product (bp)
CR-1 5-GGAATTTGCTCGTCCATCTC-3 5-ACCGTGCCAGCATTTACAC-3 307
β-catenin 5-GCAACCAAGAAAGCAAGCTC-3 5-GCTGAACAAGAGTCCCAAGG-3 303
E-cadherin 5-AAACAGGATGGCTGAAGGTG-3 5-TCTTGGCTGAGGATGGTGTA-3 295
c-myc 5-CCGAGGAGAATGTCAAGAGG-3 5-ACGCACAAGAGTTCCGTAGC-3 270
β-actin 5-CTCTTCCAGCCTTCCTTCCT-3 5-ACTCCTGCTTGCTGATCCAC-3 304

Expression correlations between CR-1, E-cadherin and β-catenin in PCa tissues for IHC.

CR-1*E-cadherin/β-catenin
E-cadherin β-catenin
− + − +
CR-1
− Count 20 5 9 16
% of total 33 8 15 27
+ Count 16 19 4 31
% of total 27 32 6 52
Total Count 36 24 13 47
% of total 60 40 21 79

Statistical analyses were performed using the Chi-square test and the McNemars statistical test.

Clinicopathological data of Cripto-1 in PCa.

Clinical data N CR-1- (%) CR-1+ (%) P-value
Age at registration (years)
  ≥70 25 10 (40.00) 15 (60.00) 0.825
  <70 35 15 (42.86) 20 (57.14)
Serum PSA (ng/ml)
<4 2 1 (50.00) 1 (50.00)
4–10 9 8 (88.89) 1 (11.11) 0.007a
>10 49 16 (32.65) 33 (67.35)
Gleason score
<7 9 4 (44.44) 5 (55.56) 0.032b
7 18 3 (16.67) 15 (83.33)
>7 33 18 (54.55) 15 (45.45)
Clinical stage
I–II 27 16 (59.26) 11 (40.74) 0.012b
III–IV 33 9 (27.27) 24 (72.73)
Lymph node metastasis
No 15 10 (66.67) 5 (33.33) 0.023b
Yes 45 15 (33.33) 30 (66.67)

Statistical analyses were performed using the Chi-square test.

P<0.01,

P<0.05.